Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Elife|April 19, 2021
Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responsesStephan Wilmes, Polly-Anne Jeffrey, Jonathan Martinez-Fabregas, et al.Nature Communications|April 22, 2020
Molecular profiling of driver events in metastatic uveal melanomaJoakim Karlsson, Lisa M Nilsson, Suman Mitra, et al.The Journal of Allergy and Clinical Immunology|August 2, 2022
Allergic sensitization impairs lung resident memory CD8 T-cell response and virus clearanceKomal Agrawal, Li Ching Ong, Susan Monkley, et al.Iscience|March 21, 2024
MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myelomaLama Hasan Bou Issa, Léa Fléchon, William Laine, et al.Journal of Medicinal Chemistry|September 22, 2023
Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical CharacterizationMagnus Nilsson, Kristina Berggren, Susanne Berglund, et al.Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.Proceedings of the National Academy of Sciences of the United States of America|March 4, 2020
Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunityDalton Hermans, Sanjivan Gautam, Juan C García-Cañaveras, et al.Science Immunology|December 2, 2022
IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective muteinSilvia Gaggero, Jonathan Martinez-Fabregas, Adeline Cozzani, et al.Nature Communications|January 22, 2021
Universal toxin-based selection for precise genome engineering in human cellsSongyuan Li, Nina Akrap, Silvia Cerboni, et al.Nature|September 16, 2021
An engineered IL-2 partial agonist promotes CD8+ T cell stemnessFei Mo, Zhiya Yu, Peng Li, et al.Pageof 5